Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 538

Jan 11 (Reuters) — The University of Oxford said on Thursday it had begun human testing of an experimental vaccine against the brain-swelling Nipah virus that led to outbreaks in India’s Kerala state and other parts of Asia.

There is no vaccine yet for the deadly virus. Nipah was first identified about 25 years ago in Malaysia and has led to outbreaks in Bangladesh, India and Singapore.

The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India’s COVID-19 shots.

Read more | >

Ancient DNA helps explain why northern Europeans have a higher risk of multiple sclerosis than other ancestries: It’s a genetic legacy of horseback-riding cattle herders who swept into the region about 5,000 years ago.

The findings come from a huge project to compare modern DNA with that culled from ancient humans’ teeth and bones — allowing scientists to trace both prehistoric migration and disease-linked genes that tagged along.

When a Bronze Age people called the Yamnaya moved from the steppes of what are now Ukraine and Russia into northwestern Europe, they carried gene variants that today are known to increase people’s risk of multiple sclerosis, researchers reported Wednesday.

Read more | >

CRISPR pioneer Jennifer Doudna, Ph.D., looks set to continue to push the boundaries of gene editing, as she announces plans to team up with life sciences giant Danaher to create a center focused on generating new therapies for rare and other diseases.

The center, which will be based at the headquarters of Doudna’s own Innovative Genomics Institute (IGI) and referred to as the Danaher-IGI Beacon for CRISPR Cures, “aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach,” according to a Jan. 9 release from Danaher.

Read more | >

An unexpected genetic discovery in wheat has led to opportunities for the metabolic engineering of versatile compounds with the potential to improve its nutritional qualities and resilience to disease.

Researchers in the Osbourn group at the John Innes Centre have been investigating biosynthetic gene clusters in wheat – groups of genes that are co-localized on the genome and work together to produce specific molecules.

Read more | >

Background: The Promise of Prime Editing

Prime editing is a promising technology for changing genomic deoxyribonucleic acid (DNA) that has the potential to be used to cure genetic diseases in individuals. Prime editors are proteins that can replace a specific deoxyribonucleic acid sequence with another. PE systems necessitate three distinct nucleic acid hybridizations and are not dependent on double-strand deoxyribonucleic acid breaks or donor deoxyribonucleic acid templates.

Researchers must devise efficient and safe techniques to deliver prime editors in tissues in the in vivo settings to fulfill PE’s objective. While viral delivery techniques such as adenoviruses and adeno-associated viruses (AAVs) can transport PE in vivo, non-viral delivery techniques like lipid nanoparticles can sidestep these concerns by packaging PEs as temporarily expressing messenger ribonucleic acids.

Read more | >

Antibodies are used in many kinds of cancer treatments but have only been able to reach proteins on the outside of cancer cells—until now. According to a new study, scientists have designed antibodies that can barge into cancer cells and drag abnormal proteins out, ultimately slowing tumor growth in mice.

The approach is a novel way of targeting cancer-fueling proteins that are buried inside cancer cells, several experts said.

Most antibodies can’t get inside cells. Yet most cancer-fueling proteins are tucked deep inside cancer cells. One type of antibody, however, called IgA, can glide through certain cells like a ghost walking through a wall.

Read more | >

NCI researchers have found a persistent decline in rates of both smoking-related and non-smoking-related lung cancer deaths.

In the U.S., lung cancer death rates have declined for decades, primarily due to decreases in cigarette smoking. However, it is unclear whether rates of smoking-unrelated lung cancer deaths are also decreasing. If the rates are increasing, that may suggest increases in exposure to other lung carcinogens that need to be investigated. Meredith Shiels, Ph.D., M.H.S., senior investigator in the Infections and Immunoepidemiology Branch, and colleagues in the Biostatistics Branch, the Division of Cancer Control and Population Sciences, and Information Management Services, conducted a study to estimate trends in U.S. lung cancer death rates from 1991–2018. They found that both smoking-attributable and smoking-unrelated lung cancer death rates declined over this period. The findings were published in the Journal of the National Cancer Institute on December 9, 2023.

Cancer registries and death certificates do not collect the smoking status of every person diagnosed with or who died from lung cancer. Thus, to estimate trends in lung cancer death rates by smoking status, the researchers needed another way to determine the age-specific trends in lung cancer deaths attributed to smoking, and unrelated to smoking. They estimated age-specific annual percentage of lung cancer deaths that could be attributed to smoking using smoking status data from the National Health Interview Survey linked to death certificate data. These population attributable fractions were then multiplied by national data on lung cancer mortality to estimate trends over time in smoking-attributable and smoking-unrelated deaths. The researchers found that the fraction of lung cancer deaths attributable to smoking decreased from 82% in 1991 to 75% in 2018. Over this same period, smoking-attributable lung cancer death rates declined 2.

Read more | >